Retrospective study of surgical and oncological outcomes of patients with borderline ovarian tumors treated at Pius Hospital Oldenburg, Germany, between 2009-2014.

Retrospective study of surgical and oncological outcomes of patients with borderline ovarian tumors treated at Pius Hospital Oldenburg, Germany, between 2009-2014. - COPBOT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009512

Enrollment

Registered

2023-04-18

Start date

2017-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D39.1

Interventions

Group 1: Surgical and oncological outcomes of patients with confirmed borderline ovarian tumors who underwent surgical treatment, via laparotomy or laparoscopy, between 2009 and 2014.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Cases with confirmed diagnosis of BOT according to histological classification based on WHO-criteria histological findings. 2. Cases received no other treatment for BOT except for surgery 3. Primary surgical treatment was either a laparoscopic or laparotomy procedure, including both conservative and radical surgery 4. Any level of CA 125 prior to treatment

Exclusion criteria

Exclusion criteria: 1. All those cases of ovarian tumors without confirmed diagnosis of BOT 2. All those cases with BOT without surgical treatment 3. All cases of ovarian tumors diagnosed before January 2009 and after December 2014

Design outcomes

Primary

Measure	Time frame
To compare the surgical and oncological outcomes of patients with BOT after laparotomy or laparoscopic surgical procedures performed between 2009 and 2014 at the University Clinic of Gynecology of the Pius Hospital Oldenburg	—

Secondary

Measure	Time frame
1. To describe the clinical patient characteristics and risk factors at time of diagnosis for patients with BOT. 2. To estimate frequency of BOT according to histological features and staging. 3. To estimate the median duration of surgery according to tumor size. 4. To estimate the rate of complications of primary and second-look procedures according to surgical approach. 5. To estimate recurrence rates after radical and conservative surgical treatment according to surgical approach. 6. To estimate recurrence rates after incomplete surgical staging according to surgical approach. 7. To estimate recurrence rates according to histological findings and staging of primary BOT. 8. To estimate malignant transformation rates during follow-up. 9. To estimate progression-free survival rates according to surgical approach. 10. To estimate pregnancy rates after conservative fertility sparing surgery according to surgical approach. 11. To estimate whether the predictive value of DNA ploidy as a dependent factor on tumor recurrence rate.	—

Measure

Time frame

1. To describe the clinical patient characteristics and risk factors at time of diagnosis for patients with BOT. 2. To estimate frequency of BOT according to histological features and staging. 3. To estimate the median duration of surgery according to tumor size. 4. To estimate the rate of complications of primary and second-look procedures according to surgical approach. 5. To estimate recurrence rates after radical and conservative surgical treatment according to surgical approach. 6. To estimate recurrence rates after incomplete surgical staging according to surgical approach. 7. To estimate recurrence rates according to histological findings and staging of primary BOT. 8. To estimate malignant transformation rates during follow-up. 9. To estimate progression-free survival rates according to surgical approach. 10. To estimate pregnancy rates after conservative fertility sparing surgery according to surgical approach. 11. To estimate whether the predictive value of DNA ploidy as a dependent factor on tumor recurrence rate.

—

Countries

Germany

Contacts

Public ContactAngelika Larbig

Pius-Hospital OldenburgAbteilung Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie

gyn-sekretariat@pius-hospital.de0441 2291501

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026